PC
MYGN icon

Palo Capital’s Myriad Genetics MYGN Stock Holding History

Palo Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-18,570
Closed -$657K – 135
2015
Q1 		$657K Sell
18,570
-6,100
-25% -$218K 0.54% 88
2014
Q4 		$840K Buy
+24,670
New +$875K 0.71% 66

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Palo Capital's MYGN Position: Q2 2015 in Review

Palo Capital sold out of Myriad Genetics (MYGN) in Q2 2015, closing a stake of 18,570 shares — an estimated $657K sold.

Palo Capital first reported a position in MYGN in Q4 2014 and held it in 2 quarters. The position peaked at $840K in Q4 2014. 234 funds tracked by Wall St. Rank hold MYGN as of Q2 2015.

  • Palo Capital reported no remaining Myriad Genetics position as of Q2 2015 after selling out during the quarter.
  • Palo Capital sold 18,570 Myriad Genetics shares in Q2 2015, an estimated $657K.
  • Palo Capital first reported a position in Myriad Genetics in Q4 2014 and held it in 2 quarters.
  • Palo Capital's Myriad Genetics position peaked at $840K in Q4 2014.
  • 234 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2015.

Based on Palo Capital's 13F filing for Q2 2015, filed 10 Aug 2015.